Cargando…
Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab – Differences and Similarities in Comparison to “endogenous” autoimmune Type A Gastritis and a review of literature
Immune checkpoint inhibitors are increasingly used in advanced malignant diseases and are well-known for their good results. With the blockade of immune checkpoints, the probability of immune-related adverse events is also increased. We present a 54-year-old female patient with advanced NSCLC. She w...
Autores principales: | Ecker, Miriam Eva, Weckauf, Helgard, Tebbe, Sandra, Schuppert, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10562045/ https://www.ncbi.nlm.nih.gov/pubmed/36963423 http://dx.doi.org/10.1055/a-2000-5705 |
Ejemplares similares
-
Immune checkpoint inhibitor‐related gastritis in a patient with metastatic melanoma
por: Sugiyama, Yuya, et al.
Publicado: (2021) -
Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy
por: Gaffuri, P., et al.
Publicado: (2019) -
Immune Checkpoint Inhibitor-Induced Hemorrhagic Gastritis
por: Mathialagan, Karthik, et al.
Publicado: (2023) -
Autoimmune gastritis
por: Kulnigg-Dabsch, Stefanie
Publicado: (2016) -
Hashimoto’s Thyroiditis and Autoimmune Gastritis
por: Cellini, Miriam, et al.
Publicado: (2017)